Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, produced by Streptomyces strains | 1048 | 114-07-8 |
Dose | Unit | Route |
---|---|---|
1 | g | O |
2 | g | O |
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 2.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 90.88 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 35 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.95 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.10 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 24, 1964 | FDA | ARBOR PHARMS LLC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 4895.11 | 12.29 | 2234 | 18180 | 248776 | 50335934 |
International normalised ratio fluctuation | 198.30 | 12.29 | 61 | 20353 | 2129 | 50582581 |
Bloody discharge | 129.14 | 12.29 | 38 | 20376 | 1136 | 50583574 |
Lyme disease | 93.14 | 12.29 | 36 | 20378 | 2507 | 50582203 |
Seronegative arthritis | 89.34 | 12.29 | 33 | 20381 | 2028 | 50582682 |
Exposure during pregnancy | 66.33 | 12.29 | 149 | 20265 | 120866 | 50463844 |
Necrosis ischaemic | 62.89 | 12.29 | 20 | 20394 | 779 | 50583931 |
Anaphylactic reaction | 60.93 | 12.29 | 91 | 20323 | 53964 | 50530746 |
Wheezing | 51.60 | 12.29 | 91 | 20323 | 61956 | 50522754 |
Dislocation of vertebra | 51.25 | 12.29 | 25 | 20389 | 3062 | 50581648 |
Faecal volume decreased | 50.77 | 12.29 | 12 | 20402 | 148 | 50584562 |
Beta haemolytic streptococcal infection | 50.06 | 12.29 | 21 | 20393 | 1809 | 50582901 |
Pneumonia streptococcal | 48.96 | 12.29 | 20 | 20394 | 1611 | 50583099 |
Drug interaction | 48.01 | 12.29 | 183 | 20231 | 199438 | 50385272 |
Amniotic cavity infection | 44.51 | 12.29 | 17 | 20397 | 1146 | 50583564 |
Vomiting | 42.95 | 12.29 | 325 | 20089 | 460433 | 50124277 |
Rash | 39.87 | 12.29 | 307 | 20107 | 437164 | 50147546 |
Pneumococcal infection | 39.52 | 12.29 | 12 | 20402 | 400 | 50584310 |
Ototoxicity | 37.91 | 12.29 | 15 | 20399 | 1112 | 50583598 |
Completed suicide | 36.44 | 12.29 | 5 | 20409 | 131884 | 50452826 |
Umbilical erythema | 36.14 | 12.29 | 8 | 20406 | 72 | 50584638 |
Death | 35.14 | 12.29 | 48 | 20366 | 325331 | 50259379 |
Vertigo positional | 34.82 | 12.29 | 18 | 20396 | 2493 | 50582217 |
Abortion spontaneous | 34.37 | 12.29 | 61 | 20353 | 41711 | 50542999 |
Drug intolerance | 33.80 | 12.29 | 176 | 20238 | 218928 | 50365782 |
Purpura senile | 32.58 | 12.29 | 11 | 20403 | 518 | 50584192 |
Death neonatal | 32.19 | 12.29 | 9 | 20405 | 223 | 50584487 |
Caesarean section | 31.30 | 12.29 | 35 | 20379 | 15604 | 50569106 |
Spondylitis | 30.09 | 12.29 | 17 | 20397 | 2808 | 50581902 |
Bronchial obstruction | 29.36 | 12.29 | 13 | 20401 | 1277 | 50583433 |
Tarsal tunnel syndrome | 28.50 | 12.29 | 10 | 20404 | 529 | 50584181 |
Pain | 28.24 | 12.29 | 129 | 20285 | 578774 | 50005936 |
Premature baby | 26.82 | 12.29 | 35 | 20379 | 18302 | 50566408 |
Mass excision | 26.51 | 12.29 | 8 | 20406 | 261 | 50584449 |
Drug tolerance decreased | 26.50 | 12.29 | 25 | 20389 | 9135 | 50575575 |
Stevens-Johnson syndrome | 26.49 | 12.29 | 38 | 20376 | 21714 | 50562996 |
Serum sickness-like reaction | 25.91 | 12.29 | 9 | 20405 | 462 | 50584248 |
Fall | 25.74 | 12.29 | 61 | 20353 | 334871 | 50249839 |
Wound infection | 25.71 | 12.29 | 28 | 20386 | 12120 | 50572590 |
Lip swelling | 25.54 | 12.29 | 40 | 20374 | 24696 | 50560014 |
Therapeutic product effect incomplete | 24.56 | 12.29 | 87 | 20327 | 91428 | 50493282 |
Oligohydramnios | 23.29 | 12.29 | 19 | 20395 | 5731 | 50578979 |
Breast cancer stage III | 22.85 | 12.29 | 15 | 20399 | 3241 | 50581469 |
Infection | 22.67 | 12.29 | 133 | 20281 | 172821 | 50411889 |
Premature rupture of membranes | 22.58 | 12.29 | 17 | 20397 | 4563 | 50580147 |
Resorption bone increased | 22.41 | 12.29 | 10 | 20404 | 1001 | 50583709 |
Spinal fusion surgery | 22.34 | 12.29 | 16 | 20398 | 3979 | 50580731 |
Adjustment disorder with depressed mood | 22.31 | 12.29 | 14 | 20400 | 2800 | 50581910 |
Abdominal pain upper | 21.85 | 12.29 | 124 | 20290 | 159185 | 50425525 |
Drug ineffective | 20.86 | 12.29 | 221 | 20193 | 819112 | 49765598 |
Vestibular disorder | 20.24 | 12.29 | 10 | 20404 | 1259 | 50583451 |
Mucous stools | 19.47 | 12.29 | 13 | 20401 | 2889 | 50581821 |
Ergot poisoning | 19.09 | 12.29 | 5 | 20409 | 96 | 50584614 |
Pharyngeal oedema | 19.05 | 12.29 | 25 | 20389 | 13140 | 50571570 |
Maternal drugs affecting foetus | 18.94 | 12.29 | 16 | 20398 | 5061 | 50579649 |
Urticaria | 18.53 | 12.29 | 102 | 20312 | 129459 | 50455251 |
Corneal neovascularisation | 18.49 | 12.29 | 5 | 20409 | 109 | 50584601 |
Corneal perforation | 18.28 | 12.29 | 7 | 20407 | 475 | 50584235 |
Acute generalised exanthematous pustulosis | 17.88 | 12.29 | 20 | 20394 | 8918 | 50575792 |
Stenotrophomonas infection | 17.66 | 12.29 | 10 | 20404 | 1659 | 50583051 |
Nasopharyngitis | 17.44 | 12.29 | 32 | 20382 | 192895 | 50391815 |
Alopecia | 16.97 | 12.29 | 47 | 20367 | 245000 | 50339710 |
Infantile haemangioma | 16.32 | 12.29 | 4 | 20410 | 58 | 50584652 |
Starvation ketoacidosis | 15.90 | 12.29 | 4 | 20410 | 65 | 50584645 |
Febrile neutropenia | 15.71 | 12.29 | 10 | 20404 | 97657 | 50487053 |
Anal candidiasis | 15.63 | 12.29 | 3 | 20411 | 12 | 50584698 |
Type 2 diabetes mellitus | 15.21 | 12.29 | 39 | 20375 | 34336 | 50550374 |
Cardiac arrest neonatal | 14.39 | 12.29 | 4 | 20410 | 97 | 50584613 |
Hypersensitivity | 14.28 | 12.29 | 141 | 20273 | 215020 | 50369690 |
Prescribed overdose | 14.23 | 12.29 | 23 | 20391 | 14577 | 50570133 |
Stomatitis | 14.19 | 12.29 | 12 | 20402 | 101332 | 50483378 |
Neutropenia | 13.85 | 12.29 | 24 | 20390 | 147941 | 50436769 |
Dysphoria | 13.75 | 12.29 | 13 | 20401 | 4761 | 50579949 |
Product packaging issue | 13.60 | 12.29 | 7 | 20407 | 960 | 50583750 |
Toxicity to various agents | 13.10 | 12.29 | 43 | 20371 | 212456 | 50372254 |
Stillbirth | 13.09 | 12.29 | 14 | 20400 | 5938 | 50578772 |
Ill-defined disorder | 13.07 | 12.29 | 3 | 20411 | 54651 | 50530059 |
Anaemia | 13.01 | 12.29 | 55 | 20359 | 252401 | 50332309 |
Pseudomembranous colitis | 12.99 | 12.29 | 10 | 20404 | 2775 | 50581935 |
Premature delivery | 12.78 | 12.29 | 29 | 20385 | 23634 | 50561076 |
Blepharitis | 12.76 | 12.29 | 9 | 20405 | 2186 | 50582524 |
Renal impairment neonatal | 12.62 | 12.29 | 3 | 20411 | 38 | 50584672 |
Abdominal pain | 12.52 | 12.29 | 148 | 20266 | 236080 | 50348630 |
Haemoglobin decreased | 12.50 | 12.29 | 20 | 20394 | 127196 | 50457514 |
Fatigue | 12.41 | 12.29 | 206 | 20208 | 707395 | 49877315 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 488.24 | 15.30 | 280 | 8194 | 68126 | 29497927 |
Hyphaema | 74.49 | 15.30 | 19 | 8455 | 469 | 29565584 |
Toxic epidermal necrolysis | 68.48 | 15.30 | 50 | 8424 | 18103 | 29547950 |
Product packaging issue | 62.84 | 15.30 | 17 | 8457 | 530 | 29565523 |
Drug interaction | 61.49 | 15.30 | 158 | 8316 | 197227 | 29368826 |
Premature baby | 44.46 | 15.30 | 38 | 8436 | 17242 | 29548811 |
Dystonia | 44.06 | 15.30 | 30 | 8444 | 9719 | 29556334 |
Stupor | 39.16 | 15.30 | 18 | 8456 | 2726 | 29563327 |
Rhabdomyolysis | 35.52 | 15.30 | 63 | 8411 | 60745 | 29505308 |
Obstruction gastric | 34.75 | 15.30 | 12 | 8462 | 858 | 29565195 |
Acute generalised exanthematous pustulosis | 34.69 | 15.30 | 21 | 8453 | 5562 | 29560491 |
Coagulation time prolonged | 34.47 | 15.30 | 13 | 8461 | 1197 | 29564856 |
Intraocular pressure increased | 32.32 | 15.30 | 19 | 8455 | 4770 | 29561283 |
Foetal death | 31.26 | 15.30 | 8 | 8466 | 200 | 29565853 |
Eye pain | 30.85 | 15.30 | 26 | 8448 | 11569 | 29554484 |
Brain oedema | 29.66 | 15.30 | 26 | 8448 | 12194 | 29553859 |
Deafness bilateral | 29.52 | 15.30 | 11 | 8463 | 980 | 29565073 |
SAPHO syndrome | 28.86 | 15.30 | 6 | 8468 | 57 | 29565996 |
Pyloric stenosis | 28.62 | 15.30 | 10 | 8464 | 740 | 29565313 |
Product dispensing error | 27.49 | 15.30 | 18 | 8456 | 5462 | 29560591 |
Foetal arrhythmia | 25.86 | 15.30 | 6 | 8468 | 98 | 29565955 |
Caesarean section | 25.53 | 15.30 | 12 | 8462 | 1911 | 29564142 |
Oligohydramnios | 23.59 | 15.30 | 7 | 8467 | 306 | 29565747 |
Oculogyric crisis | 22.84 | 15.30 | 10 | 8464 | 1351 | 29564702 |
Onychophagia | 22.69 | 15.30 | 5 | 8469 | 64 | 29565989 |
Maternal drugs affecting foetus | 22.54 | 15.30 | 14 | 8460 | 3879 | 29562174 |
Low birth weight baby | 22.22 | 15.30 | 17 | 8457 | 6591 | 29559462 |
Learning disorder | 22.13 | 15.30 | 9 | 8465 | 1013 | 29565040 |
Febrile neutropenia | 22.09 | 15.30 | 3 | 8471 | 112237 | 29453816 |
Ototoxicity | 21.50 | 15.30 | 10 | 8464 | 1555 | 29564498 |
Tricuspid valve disease | 21.48 | 15.30 | 6 | 8468 | 211 | 29565842 |
Respiratory acidosis | 21.18 | 15.30 | 14 | 8460 | 4314 | 29561739 |
Sepsis neonatal | 20.67 | 15.30 | 6 | 8468 | 243 | 29565810 |
Myasthenia gravis crisis | 20.49 | 15.30 | 7 | 8467 | 484 | 29565569 |
Vasculitic rash | 20.08 | 15.30 | 8 | 8466 | 853 | 29565200 |
Torsade de pointes | 19.94 | 15.30 | 16 | 8458 | 6645 | 29559408 |
Pathogen resistance | 19.16 | 15.30 | 17 | 8457 | 8099 | 29557954 |
Swelling face | 18.72 | 15.30 | 26 | 8448 | 20324 | 29545729 |
Hepatic necrosis | 18.66 | 15.30 | 12 | 8462 | 3530 | 29562523 |
Accidental exposure to product | 18.66 | 15.30 | 19 | 8455 | 10734 | 29555319 |
Ischaemic hepatitis | 18.54 | 15.30 | 9 | 8465 | 1539 | 29564514 |
Potentiating drug interaction | 18.50 | 15.30 | 13 | 8461 | 4425 | 29561628 |
Myoglobinuria | 17.84 | 15.30 | 7 | 8467 | 717 | 29565336 |
Hepatic failure | 17.55 | 15.30 | 32 | 8442 | 31480 | 29534573 |
Measles | 17.53 | 15.30 | 5 | 8469 | 190 | 29565863 |
Cardio-respiratory arrest neonatal | 17.32 | 15.30 | 3 | 8471 | 9 | 29566044 |
Neonatal disorder | 17.14 | 15.30 | 7 | 8467 | 796 | 29565257 |
Stevens-Johnson syndrome | 16.58 | 15.30 | 22 | 8452 | 16475 | 29549578 |
Exposure during pregnancy | 16.48 | 15.30 | 16 | 8458 | 8538 | 29557515 |
Brain herniation | 15.98 | 15.30 | 11 | 8463 | 3622 | 29562431 |
Pupillary disorder | 15.92 | 15.30 | 5 | 8469 | 265 | 29565788 |
Megacolon | 15.31 | 15.30 | 8 | 8466 | 1597 | 29564456 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 3374.10 | 12.14 | 1652 | 21618 | 236163 | 64239299 |
International normalised ratio fluctuation | 190.94 | 12.14 | 62 | 23208 | 2899 | 64472563 |
Bloody discharge | 128.99 | 12.14 | 39 | 23231 | 1438 | 64474024 |
Drug interaction | 100.83 | 12.14 | 323 | 22947 | 361760 | 64113702 |
Lyme disease | 98.87 | 12.14 | 36 | 23234 | 2379 | 64473083 |
Product packaging issue | 77.59 | 12.14 | 24 | 23246 | 956 | 64474506 |
Seronegative arthritis | 69.96 | 12.14 | 29 | 23241 | 2714 | 64472748 |
Hyphaema | 64.60 | 12.14 | 19 | 23251 | 636 | 64474826 |
Necrosis ischaemic | 61.01 | 12.14 | 20 | 23250 | 963 | 64474499 |
Toxic epidermal necrolysis | 59.16 | 12.14 | 70 | 23200 | 37096 | 64438366 |
Beta haemolytic streptococcal infection | 51.62 | 12.14 | 21 | 23249 | 1873 | 64473589 |
Dislocation of vertebra | 50.54 | 12.14 | 24 | 23246 | 3100 | 64472362 |
Ototoxicity | 50.52 | 12.14 | 23 | 23247 | 2700 | 64472762 |
Pneumonia streptococcal | 50.24 | 12.14 | 22 | 23248 | 2356 | 64473106 |
Anaphylactic reaction | 47.14 | 12.14 | 87 | 23183 | 68577 | 64406885 |
Wheezing | 45.48 | 12.14 | 94 | 23176 | 80485 | 64394977 |
Stevens-Johnson syndrome | 42.55 | 12.14 | 57 | 23213 | 34192 | 64441270 |
Exposure during pregnancy | 40.80 | 12.14 | 88 | 23182 | 77587 | 64397875 |
Acute generalised exanthematous pustulosis | 37.70 | 12.14 | 35 | 23235 | 14023 | 64461439 |
Pneumococcal infection | 36.46 | 12.14 | 13 | 23257 | 808 | 64474654 |
Febrile neutropenia | 35.01 | 12.14 | 12 | 23258 | 187645 | 64287817 |
Drug intolerance | 34.67 | 12.14 | 147 | 23123 | 187845 | 64287617 |
Drug abuse | 33.88 | 12.14 | 4 | 23266 | 132370 | 64343092 |
Stupor | 33.41 | 12.14 | 23 | 23247 | 6012 | 64469450 |
Completed suicide | 33.08 | 12.14 | 20 | 23250 | 224394 | 64251068 |
Drug tolerance decreased | 32.58 | 12.14 | 24 | 23246 | 6974 | 64468488 |
Death | 32.11 | 12.14 | 80 | 23190 | 482625 | 63992837 |
Caesarean section | 32.05 | 12.14 | 29 | 23241 | 11245 | 64464217 |
Vertigo positional | 31.39 | 12.14 | 17 | 23253 | 2894 | 64472568 |
Rash | 30.96 | 12.14 | 276 | 22994 | 458273 | 64017189 |
Maternal exposure during pregnancy | 30.71 | 12.14 | 90 | 23180 | 95794 | 64379668 |
Tarsal tunnel syndrome | 30.24 | 12.14 | 10 | 23260 | 495 | 64474967 |
Purpura senile | 30.12 | 12.14 | 10 | 23260 | 501 | 64474961 |
Infection | 28.41 | 12.14 | 137 | 23133 | 184743 | 64290719 |
Coagulation time prolonged | 27.31 | 12.14 | 14 | 23256 | 2132 | 64473330 |
Intraocular pressure increased | 26.89 | 12.14 | 23 | 23247 | 8279 | 64467183 |
Lip swelling | 26.53 | 12.14 | 44 | 23226 | 31863 | 64443599 |
Torsade de pointes | 26.47 | 12.14 | 32 | 23238 | 17331 | 64458131 |
Deafness bilateral | 26.10 | 12.14 | 13 | 23257 | 1863 | 64473599 |
Breast cancer stage III | 25.97 | 12.14 | 15 | 23255 | 2890 | 64472572 |
Learning disorder | 25.60 | 12.14 | 9 | 23261 | 537 | 64474925 |
Serum sickness-like reaction | 25.53 | 12.14 | 9 | 23261 | 541 | 64474921 |
Adjustment disorder with depressed mood | 25.52 | 12.14 | 14 | 23256 | 2443 | 64473019 |
Respiratory acidosis | 25.39 | 12.14 | 24 | 23246 | 9831 | 64465631 |
Oligohydramnios | 24.96 | 12.14 | 15 | 23255 | 3109 | 64472353 |
Therapeutic product effect incomplete | 23.99 | 12.14 | 87 | 23183 | 103395 | 64372067 |
Bronchial obstruction | 23.22 | 12.14 | 13 | 23257 | 2361 | 64473101 |
Spinal fusion surgery | 22.81 | 12.14 | 15 | 23255 | 3636 | 64471826 |
Ergot poisoning | 22.63 | 12.14 | 6 | 23264 | 136 | 64475326 |
Spondylitis | 22.56 | 12.14 | 14 | 23256 | 3072 | 64472390 |
Premature rupture of membranes | 22.47 | 12.14 | 15 | 23255 | 3729 | 64471733 |
Oculogyric crisis | 22.41 | 12.14 | 13 | 23257 | 2525 | 64472937 |
Product dispensing error | 22.37 | 12.14 | 24 | 23246 | 11426 | 64464036 |
Mass excision | 22.36 | 12.14 | 7 | 23263 | 290 | 64475172 |
Corneal neovascularisation | 22.27 | 12.14 | 6 | 23264 | 145 | 64475317 |
SAPHO syndrome | 22.15 | 12.14 | 6 | 23264 | 148 | 64475314 |
Resorption bone increased | 22.09 | 12.14 | 10 | 23260 | 1158 | 64474304 |
Wound infection | 22.02 | 12.14 | 27 | 23243 | 14837 | 64460625 |
Anaemia | 21.28 | 12.14 | 68 | 23202 | 378612 | 64096850 |
Pharyngeal oedema | 21.07 | 12.14 | 27 | 23243 | 15504 | 64459958 |
Fall | 20.64 | 12.14 | 79 | 23191 | 416747 | 64058715 |
Malignant neoplasm progression | 19.73 | 12.14 | 8 | 23262 | 112863 | 64362599 |
Eye pain | 19.14 | 12.14 | 38 | 23232 | 31587 | 64443875 |
Haemoglobin decreased | 18.53 | 12.14 | 26 | 23244 | 195037 | 64280425 |
Dystonia | 18.42 | 12.14 | 28 | 23242 | 18837 | 64456625 |
Vomiting | 18.08 | 12.14 | 289 | 22981 | 550828 | 63924634 |
Asthenia | 17.61 | 12.14 | 87 | 23183 | 427957 | 64047505 |
Swelling face | 17.49 | 12.14 | 54 | 23216 | 59112 | 64416350 |
Tricuspid valve disease | 16.63 | 12.14 | 6 | 23264 | 386 | 64475076 |
Neutropenia | 16.46 | 12.14 | 39 | 23231 | 239585 | 64235877 |
Rhabdomyolysis | 16.32 | 12.14 | 71 | 23199 | 91655 | 64383807 |
Vestibular disorder | 15.75 | 12.14 | 10 | 23260 | 2283 | 64473179 |
Abdominal pain upper | 15.38 | 12.14 | 112 | 23158 | 174918 | 64300544 |
Ulcerative keratitis | 15.28 | 12.14 | 11 | 23259 | 3086 | 64472376 |
Anal candidiasis | 15.25 | 12.14 | 3 | 23267 | 16 | 64475446 |
Type 2 diabetes mellitus | 15.02 | 12.14 | 36 | 23234 | 33984 | 64441478 |
Myasthenia gravis crisis | 14.94 | 12.14 | 7 | 23263 | 877 | 64474585 |
Potentiating drug interaction | 14.54 | 12.14 | 16 | 23254 | 7836 | 64467626 |
Live birth | 14.45 | 12.14 | 19 | 23251 | 11185 | 64464277 |
Pathogen resistance | 14.25 | 12.14 | 20 | 23250 | 12523 | 64462939 |
Starvation ketoacidosis | 14.18 | 12.14 | 4 | 23266 | 115 | 64475347 |
Dermatitis allergic | 14.15 | 12.14 | 22 | 23248 | 15087 | 64460375 |
Myoglobinuria | 14.12 | 12.14 | 7 | 23263 | 993 | 64474469 |
Urticaria | 13.95 | 12.14 | 96 | 23174 | 147221 | 64328241 |
Brain oedema | 13.94 | 12.14 | 27 | 23243 | 22048 | 64453414 |
Grip strength decreased | 13.78 | 12.14 | 19 | 23251 | 11705 | 64463757 |
Walking aid user | 13.76 | 12.14 | 14 | 23256 | 6267 | 64469195 |
Hypotension | 13.69 | 12.14 | 81 | 23189 | 380893 | 64094569 |
Cardiac arrest neonatal | 13.60 | 12.14 | 3 | 23267 | 30 | 64475432 |
Maternal drugs affecting foetus | 13.52 | 12.14 | 8 | 23262 | 1612 | 64473850 |
Platelet count decreased | 13.44 | 12.14 | 25 | 23245 | 167686 | 64307776 |
Corneal perforation | 13.39 | 12.14 | 6 | 23264 | 678 | 64474784 |
Premature delivery | 13.31 | 12.14 | 24 | 23246 | 18565 | 64456897 |
Amniotic cavity infection | 12.68 | 12.14 | 6 | 23264 | 768 | 64474694 |
Abortion spontaneous | 12.64 | 12.14 | 28 | 23242 | 25115 | 64450347 |
Nasopharyngitis | 12.61 | 12.14 | 33 | 23237 | 196040 | 64279422 |
Clostridium colitis | 12.53 | 12.14 | 9 | 23261 | 2516 | 64472946 |
Pupillary disorder | 12.26 | 12.14 | 5 | 23265 | 449 | 64475013 |
Drug resistance | 12.25 | 12.14 | 34 | 23236 | 35068 | 64440394 |
Abdominal rigidity | 12.21 | 12.14 | 9 | 23261 | 2618 | 64472844 |
Documented hypersensitivity to administered product | 12.16 | 12.14 | 6 | 23264 | 842 | 64474620 |
None
Source | Code | Description |
---|---|---|
ATC | D10AF02 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne |
ATC | D10AF52 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne |
ATC | J01FA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides |
ATC | S01AA17 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
FDA CS | M0028311 | Macrolides |
FDA PE | N0000009982 | Decreased Sebaceous Gland Activity |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011500 | Protein Synthesis Inhibitors |
FDA EPC | N0000175877 | Macrolide |
FDA EPC | N0000175935 | Macrolide Antimicrobial |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute otitis media | indication | 3110003 | |
Listeriosis | indication | 4241002 | DOID:11573 |
Gonorrhea | indication | 15628003 | DOID:7551 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Pertussis | indication | 27836007 | |
Acute gonococcal urethritis | indication | 29864006 | |
Neonatal conjunctivitis | indication | 34298002 | DOID:9699 |
Gonorrhea of rectum | indication | 42746002 | |
Pneumonia due to Mycoplasma pneumoniae | indication | 46970008 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
Acute bacterial sinusitis | indication | 75498004 | |
Syphilis | indication | 76272004 | |
Pneumococcal pharyngitis | indication | 76651006 | |
Nongonococcal urethritis | indication | 84619001 | |
Acne vulgaris | indication | 88616000 | |
Urethritis due to Chlamydia trachomatis | indication | 179101003 | |
Chlamydial conjunctivitis | indication | 231861005 | DOID:13800 |
Pneumococcal pneumonia | indication | 233607000 | |
Chlamydial pneumonia | indication | 233609002 | |
Neonatal pneumonia | indication | 233619008 | |
Erythrasma | indication | 238418005 | DOID:4131 |
Streptococcus pyogenes infection | indication | 302809008 | |
Infective otitis media | indication | 312218008 | |
Diphtheria | indication | 397428000 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Recurrent Persistent Urethritis | indication | ||
Superficial Ocular Infection | indication | ||
Preoperative Bowel Preparation | indication | ||
Prevention of Bacterial Endocarditis | indication | ||
Chlamydia Cervicitis | indication | ||
Rectal Chlamydia Trachomatis Infection | indication | ||
Prevention of Neonatal Ophthalmia | indication | ||
Pneumococcal Acute Otitis Media | indication | ||
Legionnaires' Disease | indication | ||
Rheumatic Fever Prevention | indication | ||
Haemophilus Influenzae Acute Otitis Media | indication | ||
Trachoma | off-label use | 2576002 | DOID:11265 |
Inhalational anthrax | off-label use | 11389007 | |
Actinomycotic infection | off-label use | 11817007 | DOID:8478 |
Enteric campylobacteriosis | off-label use | 18081009 | |
Lyme disease | off-label use | 23502006 | DOID:11729 |
Granuloma inguinale | off-label use | 28867007 | DOID:9113 |
Sinusitis | off-label use | 36971009 | |
Erysipelas | off-label use | 44653001 | DOID:11330 |
Blepharoconjunctivitis | off-label use | 68659002 | DOID:2456 |
Cutaneous anthrax | off-label use | 84980006 | DOID:7426 |
Ecthyma | off-label use | 85791004 | |
Gastrointestinal anthrax | off-label use | 111798006 | DOID:13386 |
Bacterial conjunctivitis | off-label use | 128350005 | DOID:9700 |
Bacterial infection of skin | off-label use | 128936008 | |
Lymphogranuloma venereum | off-label use | 186946009 | DOID:13819 |
Gastroesophageal reflux disease | off-label use | 235595009 | DOID:8534 |
Gastroparesis | off-label use | 235675006 | |
Chancroid | off-label use | 266143009 | DOID:13778 |
Meibomianitis | off-label use | 309779001 | |
Infective blepharitis | off-label use | 312219000 | |
Bacterial keratitis | off-label use | 314557000 | |
Erysipeloid | off-label use | 400105005 | |
Anthrax | off-label use | 409498004 | DOID:7427 |
Relapsing fever | off-label use | 420079008 | DOID:13034 |
Gastroscopy Adjunct | off-label use | ||
Listeria Monocytogenes Septicemia | off-label use | ||
Ureaplasma Pneumonia | off-label use | ||
Torsades de pointes | contraindication | 31722008 | |
Third trimester pregnancy | contraindication | 41587001 | |
Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Cholestatic hepatitis | contraindication | 95556007 | |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Prolonged QT interval | contraindication | 111975006 | |
Hearing disorder | contraindication | 128540005 | |
Liver function tests abnormal | contraindication | 166603001 | |
Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Erythroderma | contraindication | 399992009 | |
Porphyria | contraindication | 418470004 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Inflammatory dermatosis | contraindication | 703938007 |
Species | Use | Relation |
---|---|---|
Cats | Bacterial pneumonia | Indication |
Cats | Upper respiratory infections | Indication |
Cats | Secondary infections associated with panleukopenia | Indication |
Cats | Bacterial wound infections caused by Staphylococcus species | Indication |
Cats | Bacterial wound infections caused by Streptococcus species | Indication |
Cattle | Bovine respiratory disease (BRD) associated with Pasturella multiocida | Indication |
Cattle | Mastitis caused by Staphylococcus aureus | Indication |
Cattle | Mastitis caused by Streptococcus dysgalactiae | Indication |
Cattle | Mastitis caused by Streptococcus dysgalactiae | Indication |
Cattle | Mastitis caused by Streptococcus uberis | Indication |
Chickens | Prevention and reduction of lesions and in lowering severity of chronic respiratory disease | Indication |
Chickens | Prevention of infectious coryza | Indication |
Chickens | Prevention of chronic respiratory disease during periods of stress | Indication |
Chickens | Chronic respiratory disease caused by Mycoplasma gallisepticum | Indication |
Chickens | Infectious coryza caused by Hemophilus gallinarum | Indication |
Dogs | Bacterial pneumonia | Indication |
Dogs | upper respiratory infections | Indication |
Dogs | Endometritis and metritis | Indication |
Dogs | Bacterial wound infections caused by Staphylococcus species | Indication |
Dogs | Bacterial wound infections caused by Streptococcus species | Indication |
Dogs | Bacterial wound infections caused by Corynebacterium species | Indication |
Turkeys | Chronic respiratory disease during periods of stress | Indication |
Turkeys | Prevention and reduction of lesions and in lowering severity of chronic respiratory disease | Indication |
Turkeys | Control of blue comb (nonspecific infectious enteritis) | Indication |
Product | Applicant | Ingredients |
---|---|---|
Gallimycin-100P | Bimeda Animal Health Limited | 1 |
Erythro - 100, 200, Gallimycin-100 | Bimeda Animal Health Limited | 1 |
Gallimycin PFC | Bimeda Animal Health Limited | 1 |
Erythro-36 Dry, Gallimycin-36 Dry | Bimeda Animal Health Limited | 1 |
Gallimycin-36 Sterile | Bimeda Animal Health Limited | 1 |
Erythromast 36 | Zoetis Inc. | 1 |
Erythro-100 Injection | Bimeda Animal Health Limited | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.65 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
250MG | ERYTHROMYCIN | TORRENT | A211975 | July 26, 2021 | RX | TABLET, DELAYED RELEASE | ORAL | April 2, 2022 | COMPETITIVE GENERIC THERAPY |
500MG | ERYTHROMYCIN | TORRENT | A211975 | July 26, 2021 | RX | TABLET, DELAYED RELEASE | ORAL | April 2, 2022 | COMPETITIVE GENERIC THERAPY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 7.41 | CHEMBL | |||||
Aldehyde oxidase | Enzyme | IC50 | 4.82 | WOMBAT-PK | |||||
Bile salt export pump | Transporter | IC50 | 5.39 | CHEMBL | |||||
Motilin receptor | GPCR | Ki | 4.43 | CHEMBL | |||||
Cytochrome P450 1B1 | Enzyme | IC50 | 4.40 | CHEMBL |
ID | Source |
---|---|
4017594 | VUID |
N0000145975 | NUI |
D00140 | KEGG_DRUG |
4017591 | VANDF |
4017594 | VANDF |
4017595 | VANDF |
4017596 | VANDF |
C0014806 | UMLSCUI |
CHEBI:42355 | CHEBI |
ERY | PDB_CHEM_ID |
CHEMBL2110577 | ChEMBL_ID |
CHEMBL532 | ChEMBL_ID |
CHEMBL1200506 | ChEMBL_ID |
CHEMBL3545060 | ChEMBL_ID |
CHEMBL1200510 | ChEMBL_ID |
D004917 | MESH_DESCRIPTOR_UI |
DB00199 | DRUGBANK_ID |
C010948 | MESH_SUPPLEMENTAL_RECORD_UI |
C011462 | MESH_SUPPLEMENTAL_RECORD_UI |
1456 | IUPHAR_LIGAND_ID |
C025000 | MESH_SUPPLEMENTAL_RECORD_UI |
39 | INN_ID |
4501-00-2 | SECONDARY_CAS_RN |
7704-67-8 | SECONDARY_CAS_RN |
63937KV33D | UNII |
12560 | PUBCHEM_CID |
24346 | RXNORM |
33316 | MMSL |
3627 | MMSL |
4675 | MMSL |
4678 | MMSL |
4679 | MMSL |
4680 | MMSL |
4769 | MMSL |
4799 | MMSL |
72164 | MMSL |
d00046 | MMSL |
002755 | NDDF |
002758 | NDDF |
002759 | NDDF |
002760 | NDDF |
30427009 | SNOMEDCT_US |
372694001 | SNOMEDCT_US |
39152007 | SNOMEDCT_US |
698006 | SNOMEDCT_US |
83981000 | SNOMEDCT_US |
96032005 | SNOMEDCT_US |
96033000 | SNOMEDCT_US |
23067-13-2 | SECONDARY_CAS_RN |
3847-29-8 | SECONDARY_CAS_RN |
643-22-1 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5571 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 23 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5572 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 23 sections |
ERYGEL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8075 | GEL | 20 mg | TOPICAL | NDA | 18 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8212 | GEL | 20 mg | TOPICAL | NDA authorized generic | 18 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-7191 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 18 sections |
Erythrocin Lactobionate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6476 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 13 sections |
Erythrocin Lactobionate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-6482 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | NDA | 13 sections |
erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-4024 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 18 sections |
Erythrocin Stearate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-594 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 23 sections |
Erythrocin Stearate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-595 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 23 sections |
ERYTHROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-586 | TABLET, DELAYED RELEASE | 250 mg | ORAL | ANDA | 25 sections |
ERYTHROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-588 | TABLET, DELAYED RELEASE | 500 mg | ORAL | ANDA | 25 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-606 | TABLET, COATED | 250 mg | ORAL | ANDA | 14 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-607 | TABLET, COATED | 500 mg | ORAL | ANDA | 14 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13985-605 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 18 sections |
Erythromycin Lactobionate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-116 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 24 sections |
ERYTHROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-088 | CAPSULE, DELAYED RELEASE | 250 mg | ORAL | ANDA | 22 sections |
ERY-TAB | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-089 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 27 sections |
ERYTHROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-090 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 9 sections |
ERYTHROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-091 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 17 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-070 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 19 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-173 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 15 sections |
ERYTHROMYCIN Base Filmtab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-387 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 24 sections |
ERYTHROMYCIN Base Filmtab | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-389 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 24 sections |
ERY-TAB | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-457 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 23 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-910 | OINTMENT | 5 mg | OPHTHALMIC | ANDA | 8 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24338-102 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 27 sections |
Erythromycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24338-104 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Erythrocin Stearate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24338-106 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 27 sections |
ERYTHROMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24338-120 | CAPSULE, DELAYED RELEASE | 250 mg | ORAL | ANDA | 27 sections |